Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel R Knight

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
ACS Omega|March 7, 2022
Development of 1,2,4-Oxadiazole Antimicrobial Agents to Treat Enteric Pathogens within the Gastrointestinal TractNoel P Pitcher, Jitendra R Harjani, Yichao Zhao, et al.
Current Pharmaceutical Design|March 12, 2015
Significant Differences Characterise the Correlation Coefficients between Biocide and Antibiotic Susceptibility Profiles in Staphylococcus aureusMarco R Oggioni, Joana Rosado Coelho, Leonardo Furi, et al.
Anaerobe|December 1, 2018
A series of three cases of severe Clostridium difficile infection in Australia associated with a binary toxin producing clade 2 ribotype 251 strainMichael C Wehrhahn, Caitlin Keighley, Jelica Kurtovic, et al.
European Journal of Medicinal Chemistry|March 23, 2019
Cationic biaryl 1,2,3-triazolyl peptidomimetic amphiphiles targeting Clostridioides (Clostridium) difficile: Synthesis, antibacterial evaluation and an in vivo C. difficile infection modelAndrew J Tague, Papanin Putsathit, Melanie L Hutton, et al.
Antibiotics (Basel, Switzerland)|August 27, 2021
Cationic Peptidomimetic Amphiphiles Having a <i>N</i>-Aryl- or <i>N</i>-Naphthyl-1,2,3-Triazole Core Structure Targeting <i>Clostridioides</i> (<i>Clostridium</i>) <i>difficile</i>: Synthesis, Antibacterial Evaluation, and an In Vivo <i>C. difficile</i> Infection ModelMuni Kumar Mahadari, Sreenu Jennepalli, Andrew J Tague, et al.
The Journal of Antimicrobial Chemotherapy|July 30, 2015
Surveillance for antimicrobial resistance in Australian isolates of Clostridium difficile, 2013-14Daniel R Knight, Steven Giglio, Peter G Huntington, et al.
Journal of Clinical Microbiology|August 28, 2020
Laboratory-Based Surveillance of Clostridium difficile Infection in Australian Health Care and Community Settings, 2013 to 2018Stacey Hong, Papanin Putsathit, Narelle George, et al.
The Journal of Antimicrobial Chemotherapy|April 25, 2021
Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015-18Papanin Putsathit, Stacey Hong, Narelle George, et al.
Environment International|October 8, 2024
Towards integrated cross-sectoral surveillance of pathogens and antimicrobial resistance: Needs, approaches, and considerations for linking surveillance to actionRachael Lappan, Steven L Chown, Matthew French, et al.
Microbial Genomics|May 8, 2024
Defining the phylogenetics and resistome of the major <i>Clostridioides difficile</i> ribotypes circulating in AustraliaKeeley O'Grady, Stacey Hong, Papanin Putsathit, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
ACS Omega|March 7, 2022
Development of 1,2,4-Oxadiazole Antimicrobial Agents to Treat Enteric Pathogens within the Gastrointestinal TractNoel P Pitcher, Jitendra R Harjani, Yichao Zhao, et al.
Current Pharmaceutical Design|March 12, 2015
Significant Differences Characterise the Correlation Coefficients between Biocide and Antibiotic Susceptibility Profiles in Staphylococcus aureusMarco R Oggioni, Joana Rosado Coelho, Leonardo Furi, et al.
Anaerobe|December 1, 2018
A series of three cases of severe Clostridium difficile infection in Australia associated with a binary toxin producing clade 2 ribotype 251 strainMichael C Wehrhahn, Caitlin Keighley, Jelica Kurtovic, et al.
European Journal of Medicinal Chemistry|March 23, 2019
Cationic biaryl 1,2,3-triazolyl peptidomimetic amphiphiles targeting Clostridioides (Clostridium) difficile: Synthesis, antibacterial evaluation and an in vivo C. difficile infection modelAndrew J Tague, Papanin Putsathit, Melanie L Hutton, et al.
Antibiotics (Basel, Switzerland)|August 27, 2021
Cationic Peptidomimetic Amphiphiles Having a <i>N</i>-Aryl- or <i>N</i>-Naphthyl-1,2,3-Triazole Core Structure Targeting <i>Clostridioides</i> (<i>Clostridium</i>) <i>difficile</i>: Synthesis, Antibacterial Evaluation, and an In Vivo <i>C. difficile</i> Infection ModelMuni Kumar Mahadari, Sreenu Jennepalli, Andrew J Tague, et al.
The Journal of Antimicrobial Chemotherapy|July 30, 2015
Surveillance for antimicrobial resistance in Australian isolates of Clostridium difficile, 2013-14Daniel R Knight, Steven Giglio, Peter G Huntington, et al.
Journal of Clinical Microbiology|August 28, 2020
Laboratory-Based Surveillance of Clostridium difficile Infection in Australian Health Care and Community Settings, 2013 to 2018Stacey Hong, Papanin Putsathit, Narelle George, et al.
The Journal of Antimicrobial Chemotherapy|April 25, 2021
Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015-18Papanin Putsathit, Stacey Hong, Narelle George, et al.
Environment International|October 8, 2024
Towards integrated cross-sectoral surveillance of pathogens and antimicrobial resistance: Needs, approaches, and considerations for linking surveillance to actionRachael Lappan, Steven L Chown, Matthew French, et al.
Microbial Genomics|May 8, 2024
Defining the phylogenetics and resistome of the major <i>Clostridioides difficile</i> ribotypes circulating in AustraliaKeeley O'Grady, Stacey Hong, Papanin Putsathit, et al.
Pageof 6